
Macular Disease Foundation Australia (MDFA) has welcomed the Federal Government’s decision to defer the private health insurance reclassification of intravitreal (eye) injections from 1 July 2025 to 1 July 2026 and undertake further consultation.
Read MoreWe have released new research in collaboration with the University of New South Wales which has revealed the median total cost for people living with macular disease, who also receive sight-saving eye injections, is 12 percent* ($3,621) of the annual government pension payment.
Read MoreBy The Hon. Jillian Skinner, AM, former NSW Minister for Health.This article was originally published by News Corp.
Read MoreMacular Disease Foundation Australia calls on the next Federal Government to bulk-bill sight-saving eye injections for pensioners; with the potential for creating a $140 million cost-saving per year.
Read MoreThe Therapeutic Goods Administration (TGA) approval of the new eye injection treatment SYFOVRE® (pegcetacoplan) is welcome news, as it will give many people with Geographic Atrophy a treatment option that they’ve never had before to slow the progression of the disease.
Read MoreWelcome to our final Vision Voice newsletter for the year.
Read MoreMDFA has received a positive response from the people participating in our new Eye Connect support service.
Read MoreMacular Disease Foundation Australia (MDFA) has launched its new Research Impact Report, which showcases the groundbreaking projects our organisation has funded to help reduce the impact of macular disease.
Read More